Challenging disease presentation
|
|
|
|
Atypical presentation |
513 (94.1%) |
211 (38.7%) |
<0.001 |
Non-specific symptoms and signs |
82 (15.0%) |
69 (12.7%) |
0.25 |
Unfamiliar/outside specialty |
161 (29.5%) |
61 (11.2%) |
<0.001 |
Findings masking/mimicking another diagnosis |
383 (70.3%) |
210 (38.5%) |
<0.001 |
Red herring misleading findings |
83 (15.2%) |
91 (16.7%) |
0.51 |
Rapidly progressive course |
6 (1.1%) |
21 (3.9%) |
0.003 |
Slowly evolving blunting onset perception |
54 (9.9%) |
39 (7.2%) |
0.10 |
Deceptively benign course |
24 (4.4%) |
8 (1.5%) |
0.004 |
Patient factors
|
|
|
|
Language/communication barriers |
9 (1.7%) |
14 (2.6%) |
0.29 |
Signal: noise - patients with multiple other symptoms or diagnoses |
24 (4.4%) |
23 (4.2%) |
0.88 |
Failure to share data (to be forthcoming with symptoms or their severity) |
79 (14.5%) |
10 (1.8%) |
<0.001 |
Failure to follow-up |
64 (11.7%) |
4 (0.7%) |
<0.001 |
Testing challenges
|
|
|
|
Test not available due to geography, access, cost |
58 (10.6%) |
5 (0.9%) |
<0.001 |
Logistical issues in scheduling, performing |
31 (5.7%) |
2 (0.4%) |
<0.001 |
False positive/negative test limitations |
54 (9.9%) |
38 (7.0%) |
0.08 |
Performance/interpretation failures |
444 (81.5%) |
145 (26.6%) |
<0.001 |
Equivocal results/interpretation |
99 (18.2%) |
44 (8.1%) |
<0.001 |
Test follow-up issues (eg, tracking pending results) |
39 (7.2%) |
5 (0.9%) |
<0.001 |
Stressors
|
|
|
|
Time constraints for clinicians and patients |
32 (5.9%) |
2 (0.4%) |
<0.001 |
Discontinuities of care |
137 (25.1%) |
1 (0.2%) |
<0.001 |
Fragmentation of care |
36 (6.6%) |
4 (0.7%) |
<0.001 |
Memory reliance/challenges |
20 (3.7%) |
3 (0.6%) |
<0.001 |
Broader challenges
|
|
|
|
Recognition of acuity/severity |
91 (16.7%) |
43 (7.9%) |
<0.001 |
Diagnosis of complications |
16 (2.9%) |
35 (6.4%) |
0.01 |
Recognition of failure to respond to therapy |
23 (4.2%) |
28 (5.1%) |
0.47 |
Diagnosis of the underlying aetiological cause |
44 (8.1%) |
149 (27.3%) |
<0.001 |
Recognising misdiagnosis occurrence |
77 (14.1%) |
85 (15.6%) |
0.50 |
Unclear
|
0 (0.0%) |
3 (0.6%) |
0.08 |